Home / Market News / $PTGX
fiscal.ai Corporate Catalyst Impact 75/100 ● negative

Protagenic Therapeutics Reports Third Quarter 2026 Financial Results

Nov 7, 2026, 2:16 PM UTC · Primary ticker $PTGX

Protagenic Therapeutics reported a narrower net loss in Q3 2026 due to reduced operating expenses, primarily from lower R&D and the deconsolidation of Phytanix. The company is refiling its IND for PT00114 and plans a Phase Ib study, but faces immediate capital needs to fund future development, which could impact its operational runway.

Protagenic Therapeutics reported a narrowed net loss for Q3 2026, primarily driven by a 40% reduction in operating expenses due to lower R&D, legal, accounting, and salary costs, partly attributed to the deconsolidation of Phytanix. This cost control is a positive sign, but the company reported no revenue and a very low cash balance of $76,909, indicating a significant need for additional capital to fund its planned IND filing in Q1 2027. The refiling of the IND for PT00114 and anticipated Phase Ib study are key milestones, but the immediate funding gap presents a substantial short-term risk for the company's ability to execute its development plans. Traders should monitor capital raise announcements closely, as dilution or a failure to secure funding could significantly impact the stock.

$PTGX neutral Financial results and drug development update
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.